Ad Header

PharmaLive

Slogan

The Pulse of the Pharmaceutical Industry

  • Filter By Category

  • Filter By Author

Japan approves test of iPS cells for spinal injuries

Japanese scientists will test the use of human-induced pluripotent stem cells (iPS) to treat spinal cord injuries, a health ministry panel that approved the research project said.

Read More »

Starboard gauges Bristol-Myers shareholder support for Celgene deal

Activist hedge fund Starboard Value LP asked a proxy solicitor to probe the level of support among Bristol-Myers Squibb Co. shareholders for the U.S. drug maker’s $74 billion deal to buy Celgene Corp., people familiar with the matter said.

Read More »

Nektar, Bristol combo drug shows signs of tumor reduction in bladder cancer patients

Nektar Therapeutics said some patients with advanced bladder cancer treated with a combination of the company’s experimental treatment and Bristol-Myers Squibb’s immunotherapy Opdivo showed signs of tumor reduction in an early-stage study.

Read More »

Leaving the hospital early can double the odds of going back

Patients who discharge themselves from the hospital against medical advice are twice as likely to be back within 30 days as those who leave when doctors say they are ready, a large U.S. study finds.

Read More »

Push-up capacity may predict men’s heart disease risk

The number of push-ups a man can do in the doctor’s office may be a good predictor of his risk of developing heart disease in the coming years, new research suggests.

Read More »

Bayer acquires full Vitrakvi rights from Eli Lilly’s Loxo

German drugmaker Bayer acquired all rights the company does not already own in Vitrakvi, a drug against a variety of cancers driven by a rare genetic mutation, from Eli Lilly’s Loxo Oncology.

Read More »

U.S. proposes Medicare coverage for CAR-T cancer therapies

The U.S. Centers for Medicare & Medicaid Services proposed Medicare coverage of approved CAR-T cell therapies that use the patient’s immune system to fight cancer.

Read More »

Bayer, Janssen and BMS Unveil Promising Data for Prostate Cancer at ASCO GU

At the American Society of Clinical Oncology 2019 Genitourinary Cancers Symposium (ASCO GU), companies have showcased more clinical data in presentations for prostate cancer treatment.

Read More »

Merck to further study Keytruda in prostate cancer

Merck & Co. is launching three late-stage studies for the cancer immunotherapy Keytruda as a combo treatment for prostate cancer after the drug showed anti-tumor activity in an early-stage trial.

Read More »

Irish drug trial technology firm Teckro wins $25 million injection

Ireland’s Teckro, which makes software that allows physicians to take part in drug development trials from mobile devices, has won $25 million in financial backing from investors as the company hatches longer-term plans for a stock market listing.

Read More »

Ad Right Top

MedAdNews

Extensive pharmaceutical business and marketing intelligence. For back issues, please contact MDAD@kmpsgroup.com.

February 2019 Focus: Agenda 2019, Top 10 Pipelines To Watch, Value Of Pharmaceuticals, and more!

Subscribe

Ad Right Bottom